Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Novavax Amends Co-Development Agreement With PATH 11
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13
Equity Offering 14
Novavax Raises USD57.5 Million in Public Offering of Shares 14
Novavax Plans to Raise USD75 Million in Public Offering of Shares 16
Novavax Raises USD201.2 Million in Public Offering of Common Stock 17
Novavax Raises USD115 Million in Public Offering of Shares 19
Novavax Completes Public Offering Of Shares For US$100 Million 21
Novavax Completes Private Placement Of Shares For US$27 Million 22
Novavax Completes Private Placement Of Shares For US$12.2 Million 23
Debt Offering 24
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24
Acquisition 26
Novavax Completes Acquisition Of 97.4% Interest In Isconova 26
Novavax Inc – Key Competitors 28
Novavax Inc – Key Employees 29
Novavax Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Joint Venture 30
Recent Developments 32
Financial Announcements 32
Nov 07, 2018: Novavax reports third quarter 2018 financial results 32
Aug 08, 2018: Novavax Reports second quarter 2018 financial results 34
May 09, 2018: Novavax Reports First Quarter 2018 Financial Results 36
Mar 14, 2018: Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results 37
Nov 07, 2017: Novavax Reports Third Quarter 2017 Financial Results 40
Aug 08, 2017: Novavax Reports Second Quarter 2017 Financial Results 41
May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 43
Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 44
Corporate Communications 45
Nov 01, 2018: Novavax appoints Rachel King to Board of Directors 45
Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer 46
Oct 13, 2017: Novavax Announces Leadership Change 47
May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 48
Clinical Trials 49
May 07, 2018: Novavax Reaches Significant Enrollment Milestone in the Prepare Phase 3 Trial of its RSV F Vaccine 49
Apr 02, 2018: Novavax to Present Clinical Data of RSV F Vaccine at World Vaccine Congress 50
Jul 24, 2017: Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs 51
Jul 17, 2017: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM 52
Jun 07, 2017: Novavax RSV F Vaccine Phase 2 Clinical Trial Data in Women of Child Bearing Age Published in Vaccine 53
Jan 19, 2017: Novavax Initiates Phase 2 Safety and Immunogenicity Trial of the RSV F Vaccine in Older Adults 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novavax Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novavax Amends Co-Development Agreement With PATH 11
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 13
Novavax Raises USD57.5 Million in Public Offering of Shares 14
Novavax Plans to Raise USD75 Million in Public Offering of Shares 16
Novavax Raises USD201.2 Million in Public Offering of Common Stock 17
Novavax Raises USD115 Million in Public Offering of Shares 19
Novavax Completes Public Offering Of Shares For US$100 Million 21
Novavax Completes Private Placement Of Shares For US$27 Million 22
Novavax Completes Private Placement Of Shares For US$12.2 Million 23
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24
Novavax Completes Acquisition Of 97.4% Interest In Isconova 26
Novavax Inc, Key Competitors 28
Novavax Inc, Key Employees 29
Novavax Inc, Other Locations 30
Novavax Inc, Subsidiaries 30
Novavax Inc, Joint Venture 30
List of Figures
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9